{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T23:12:39Z","timestamp":1714950759364},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,11]]},"DOI":"10.7759\/cureus.10380","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T16:41:22Z","timestamp":1599842482000},"source":"Crossref","is-referenced-by-count":2,"title":["Clinical Characteristics of Hepatitis B Virus Patients After Switching to Tenofovir Alafenamide Fumarate: A Retrospective Observational Study"],"prefix":"10.7759","author":[{"given":"Abdullah S","family":"Alghamdi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hammad S","family":"Alothmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Mogharbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazeez","family":"Albiladi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Babatin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3350\/kjhep.2011.17.2.87","article-title":"Epidemiology and prevention of hepatitis B virus infection","volume":"17","author":"Kwon SY","year":"2011","unstructured":"Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol. 2011, 17:87-95. 10.3350\/kjhep.2011.17.2.87","journal-title":"Korean J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16183307","article-title":"A global view to HBV chronic infection: evolving strategies for diagnosis, treatment and prevention in immunocompetent individuals","volume":"16","author":"Nicolini LA","year":"2019","unstructured":"Nicolini LA, Orsi A, Tatarelli P, Viscoli C, Icardi G, Sticchi L. A global view to HBV chronic infection: evolving strategies for diagnosis, treatment and prevention in immunocompetent individuals. Int J Environ Res Public Health. 2019, 16:3307. 10.3390\/ijerph16183307","journal-title":"Int J Environ Res Public Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v6.i13.589","article-title":"Update on global epidemiology of viral hepatitis and preventive strategies","volume":"6","author":"Jefferies M","year":"2018","unstructured":"Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral hepatitis and preventive strategies. World J Clin Cases. 2018, 6:589-599. 10.12998\/wjcc.v6.i13.589","journal-title":"World J Clin Cases"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5144\/0256-4947.1988.474","article-title":"Hepatitis B infection in Saudi Arabia","volume":"8","author":"Al-Faleh FZ","year":"1988","unstructured":"Al-Faleh FZ. Hepatitis B infection in Saudi Arabia. Ann Saudi Med. 1988, 8:474-480. 10.5144\/0256-4947.1988.474","journal-title":"Ann Saudi Med"},{"key":"ref5","article-title":"Saudi Arabian expatriate worker fitness-screening programme: a review of 14 years of data","volume":"19","author":"Alswaidi FM","year":"2013","unstructured":"Alswaidi FM, Memish ZA, Al Hakeem RF, Atlam SA. Saudi Arabian expatriate worker fitness-screening programme: a review of 14 years of data. East Mediterr Heal J. 2013, 19:664-670.","journal-title":"East Mediterr Heal J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22962","article-title":"Hepatitis B and hepatocellular carcinoma","volume":"49","author":"Di Bisceglie AM","year":"2009","unstructured":"Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology. 2009, 49:56-60. 10.1002\/hep.22962","journal-title":"Hepatology"},{"key":"ref7","article-title":"Selective intraoperative cholangiography in laparoscopic cholecystectomy","volume":"111","author":"Giulea C","year":"2016","unstructured":"Giulea C, Enciu O, B\u00eerc\u01ce T, Miron A. Selective intraoperative cholangiography in laparoscopic cholecystectomy. Chirurgia. 2016, 111:26-32.","journal-title":"Chirurgia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2014.00022","article-title":"Antiviral therapy of liver cirrhosis related to hepatitis B virus infection","volume":"2","author":"Lu L-G","year":"2014","unstructured":"Lu L-G. Antiviral therapy of liver cirrhosis related to hepatitis B virus infection. J Clin Transl Hepatol. 2014, 2:197-201. 10.14218\/JCTH.2014.00022","journal-title":"J Clin Transl Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00599-13","article-title":"Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine","volume":"57","author":"Jones SA","year":"2013","unstructured":"Jones SA, Murakami E, Delaney W, Furman P, Hu J. Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine. Antimicrob Agents Chemother. 2013, 57:4181-4189. 10.1128\/AAC.00599-13","journal-title":"Antimicrob Agents Chemother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2016.04.015","article-title":"Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)","volume":"119","author":"De Clercq E","year":"2016","unstructured":"De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol. 2016, 119:1-7. 10.1016\/j.bcp.2016.04.015","journal-title":"Biochem Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1756284818786108","article-title":"Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence","volume":"11","author":"Byrne R","year":"2018","unstructured":"Byrne R, Carey I, Agarwal K. Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. Therap Adv Gastroenterol. 2018, 11:10.1177\/1756284818786108","journal-title":"Therap Adv Gastroenterol"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults","volume":"63","author":"Ruane PJ","year":"2013","unstructured":"Ruane PJ, Dejesus E, Berger D, et al.. Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. Journal of Acquired Immune Deficiency Syndromes. 2013, 63:449-455.","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault NA","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al.. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018, 67:1560-1599. 10.1002\/hep.29800","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"The summarized of EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"28","author":"Idilman R","year":"2017","unstructured":"Idilman R. The summarized of EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. Turkish J Gastroenterol. 2017, 28:412-416. 10.1016\/j.jhep.2017.03.021","journal-title":"Turkish J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4103\/1319-3767.126311","article-title":"SASLT practice guidelines for the management of hepatitis B virus","volume":"20","author":"Al-Hamoudi W","year":"2014","unstructured":"Al-Hamoudi W, Abaalkhail F, Elsiesy H, Alghamdi MY, Alalwan A, AlMasri N, Al-Hamoudi W. SASLT practice guidelines for the management of hepatitis B virus. Saudi J Gastroenterol. 2014, 20:5-25. 10.4103\/1319-3767.126311","journal-title":"Saudi J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft DW","year":"1976","unstructured":"Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976, 16:31-41. 10.1159\/000180580","journal-title":"Nephron"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"Elm E von","year":"2007","unstructured":"Elm E von, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007, 335:806-808. 10.7326\/0003-4819-147-8-200710160-00010","journal-title":"BMJ"},{"key":"ref18","article-title":"EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","author":"Castera L","year":"2015","unstructured":"Castera L, Yuen Chan HL, Arrese M, et al.. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015, 63:237-264.","journal-title":"J Hepatol"},{"key":"ref19","unstructured":"Vemlidy (tenofovir alafenamide). (2013). https.\/\/search.proquest.com\/openview\/1156ede5cbe165d5af92d8e1a430b0d4\/1?cbl=136155&pq-origsite=gscholar&utm_campaign=...."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00138-06","article-title":"Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus","volume":"50","author":"Delaney WE","year":"2006","unstructured":"Delaney WE, Ray AS, Yang H, et al.. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006, 50:2471-2477. 10.1128\/AAC.00138-06","journal-title":"Antimicrob Agents Chemother"},{"key":"ref21","article-title":"Tenofovir alafenamide fumarate - a new generation of tenofovir [Article in Czech]","volume":"22","author":"Snopkov\u00e1 S","year":"2016","unstructured":"Snopkov\u00e1 S, Havl\u00ed\u010dkov\u00e1 K, Husa P. Tenofovir alafenamide fumarate - a new generation of tenofovir [Article in Czech]. Klin Mikrobiol Infekc Lek. 2016, 22:111-117.","journal-title":"Klin Mikrobiol Infekc Lek"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus","volume":"125","author":"Ray AS","year":"2016","unstructured":"Ray AS, Fordyce MW, Hitchcock MJM. Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus. Antiviral Res. 2016, 125:63-70. 10.1016\/j.antiviral.2015.11.009","journal-title":"Antiviral Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1428561","article-title":"Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?","volume":"16","author":"Vigan\u00f2 M","year":"2018","unstructured":"Vigan\u00f2 M, Loglio A, Grossi G, Lampertico P. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?. Expert Rev Anti Infect Ther. 2018, 16:153-161. 10.1080\/14787210.2018.1428561","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti M","year":"2016","unstructured":"Buti M, Gane E, Seto WK, et al.. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016, 1:196-206. 10.1016\/S2468-1253(16)30107-8","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan HLY","year":"2016","unstructured":"Chan HLY, Fung S, Seto WK, et al.. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016 Nov, 1:185-95. 10.1016\/S2468-1253(16)30024-3","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25515","article-title":"Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B","volume":"91","author":"Hagiwara S","year":"2019","unstructured":"Hagiwara S, Nishida N, Ida H, et al.. Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B. J Med Virol. 2019, 91:1804-1810. 10.1002\/jmv.25515","journal-title":"J Med Virol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico P","year":"2017","unstructured":"Lampertico P, Agarwal K, Berg T, et al.. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017, 67:370-398. 10.1016\/j.jhep.2017.03.021","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-IDDFabstracts.208","article-title":"IDDF2018-ABS-0107 efficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF)","volume":"67","author":"Chan HL-Y","unstructured":"Chan HL-Y, Buti M, Flisiak R, et al.. IDDF2018-ABS-0107 efficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF). Gut. Ltd and British Society of Gastroenterology; 2018. p, 67:A97. 10.1136\/gutjnl-2018-IDDFabstracts.208","journal-title":"Gut"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1080\/13651501.2018.1508724","article-title":"Switching medication products during the treatment of psychiatric illness","volume":"23","author":"Blier P","year":"2019","unstructured":"Blier P, Margolese HC, Wilson EA, Boucher M. Switching medication products during the treatment of psychiatric illness. Int J Psychiatry Clin Pract. 2019, 23:2-13. 10.1080\/13651501.2018.1508724","journal-title":"Int J Psychiatry Clin Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/38568-clinical-characteristics-of-hepatitis-b-virus-patients-after-switching-to-tenofovir-alafenamide-fumarate-a-retrospective-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:23:11Z","timestamp":1707506591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/38568-clinical-characteristics-of-hepatitis-b-virus-patients-after-switching-to-tenofovir-alafenamide-fumarate-a-retrospective-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.10380","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,11]]}}}